IBIO Stock Forecast: iBio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.80
+0.01% on the day

The median 12-month analyst price target for iBio, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 32 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$56.4M
Ticker Nerd rank
32/ 100
Median analyst target
$6.00
Analysts covering
9
Revenue$0.0−100.0% y/y
Operating income−$6.4M
Net income−$10.6M
Free cash flow−$6.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.6%
1M
−2.4%
YTD
−58.5%
1Y
−20.0%
From 52W high
−73.9%
From 52W low
+12.7%
$0.71
$3.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores iBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
32/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
67
Revisions
55
Volatility
47
Growth
46
Issuance
35
Momentum
35
Quality
25
Value
9

Accruals (67): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (9): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26IBIOHigh $7.00Median $6.00Low $4.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9
Buy
0
Hold
0
Sell
$4.20
Low
$6.00
Median
$7.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Sept 2026HC Wainwright & Co.InitiatesBuy$7.00
2 July 2026Chardan CapitalMaintainsBuy$5.00
8 June 2026Raymond JamesInitiatesOutperform—
9 Apr 2026Chardan CapitalMaintainsBuy—
18 Mar 2026Chardan CapitalMaintainsBuy—
3 Mar 2026Jones TradingInitiatesBuy—
12 Feb 2026Chardan CapitalMaintainsBuy—
21 Oct 2025OppenheimerInitiatesOutperform—
17 Oct 2025Leerink PartnersInitiatesOutperform—
25 June 2025Chardan CapitalMaintainsBuy—
6 May 2025Chardan CapitalMaintainsBuy—
5 May 2025Chardan CapitalMaintainsBuy—
17 Dec 2024LUCID CAPITAL MARKETSInitiatesBuy—
22 July 2024Brookline CapitalInitiatesBuy—
3 June 2024Chardan CapitalMaintainsBuy—
28 May 2024Chardan CapitalInitiatesBuy—
16 Feb 2023JMP SecuritiesDowngradeMarket Perform—
7 Oct 2022Cantor FitzgeraldDowngradeNeutral$2.50 → $0.17
29 Nov 2021JMP SecuritiesInitiatesOutperform$1.50
22 Jan 2021Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IBIO.

Market Radar

This page is one stock. Monday covers all of them.

IBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, iBio, Inc. returned −20.0% against +6.9% for the S&P 500, dividends included.

IBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300Jan 26Apr 26Jul 26Oct 26IBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
52.4×

Cheaper than 5% of US stocks

Price / book
0.7×

Cheaper than 82% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−51.8%

Higher than 21% of US stocks

Return on assets
−26.6%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • iBio, Inc. has a market value of $56.4M.

  • Revenue in the twelve months to 30 June 2026: $100K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$33.0M, a −33044.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$23.8M.

  • Shares outstanding: 55.7M.

  • iBio, Inc. employs 23 people — $4K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

IBIO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IBIOiBio, Inc.$56.4M32
TENXTenax Therapeutics, Inc.$56.9M24
CGTXCognition Therapeutics, Inc.$55.4M47
CHRSCoherus Oncology, Inc.$55.3M38
AZRAzora Therapeutics, Inc.$55.0M16
OKYOOKYO Pharma Ltd.$55.0M26
AVXLAnavex Life Sciences Corp.$54.8M20

Take a look at IBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own iBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IBIO

What is the IBIO stock price forecast for 2026-2027?

The median 12-month analyst price target for iBio, Inc. is $6, with estimates ranging from $4.2 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IBIO stock a buy right now?

Of the 9 analysts covering iBio, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks iBio, Inc. 32 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IBIO?

As at 21 Nov 2026, iBio, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (67 of 100).

Will IBIO stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts is $6, and Ticker Nerd's factor model ranks iBio, Inc. 32 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IBIO stock forecast for 2030?

No analyst covering iBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.2 to $7 over the next 12 months.

How has IBIO stock performed over the past year?

iBio, Inc. returned -20.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does iBio, Inc. do?

iBio, Inc. is a biotechnology company focused on developing precision antibodies and other next-generation biologics for obesity, cardiometabolic disease, cancer, and other hard-to-treat conditions. The company uses artificial intelligence, advanced computational biology, and proprietary discovery platforms to identify and optimize antibody candidates against challenging therapeutic targets.

Company

About iBio, Inc.

iBio, Inc. is a biotechnology company focused on developing precision antibodies and other next-generation biologics for obesity, cardiometabolic disease, cancer, and other hard-to-treat conditions. The company uses artificial intelligence, advanced computational biology, and proprietary discovery platforms to identify and optimize antibody candidates against challenging therapeutic targets. Its current technology stack includes platforms designed for antibody engineering, masking, optimization, and epitope steering, which support preclinical research and early-stage pipeline development. iBio’s work is centered on improving the speed and precision of drug discovery for complex diseases, with an emphasis on antibody-based therapies and related biopharmaceutical programs. Founded in 2008 and headquartered in San Diego, California, iBio plays a niche role in the biotechnology market as a research-driven company advancing AI-enabled biologic discovery.

CEO Dr. Martin B. Brenner D.V.M., Ph.D. · 23 employees · United States · https://ibioinc.com